Table 1 Clinical and pathologic features of patients and tumors used for the analysis of OSCs
PCa Patients | Age | PSA (ng/ml) | Pathological Gleason Score | Pathological Stage |
|---|---|---|---|---|
osc#52 | 69 | 6,2 | 7 (3 + 4) | pT3a pNx pMx |
osc#53 | 63 | 13.8 | 7 (3 + 4) | pT3a pN0 pMx |
osc#54 | 66 | 2,4 | 7 (3 + 4) | pT3a pNx pMx |
osc#56 | 64 | 20 | 7 (3 + 4) | pT2c pNx pM0 |
osc#57 | 77 | 15.2 | 9 (4 + 5) | pT3b pN0 pMx |
osc#58 | 73 | 6.7 | 7 (3 + 4) | pT3a pN1 pMx |
osc#59 | 70 | 8.2 | 7 (3 + 4) | pT2 pN0 pMx |
osc#63 | 67 | 8 | 7 (3 + 4) | pT2c pNx pMx |
osc#64 | 62 | 13 | 7 (3 + 4) | pT3a pN0 pMx |
osc#65 | 75 | 7.6 | 7 (3 + 4) | pT2c pN0 pMx |
osc#66 | 71 | 9.9 | 7 (4 + 3) | pT3b pN1 pMx |
osc#67 | 69 | 9 | 7 (3 + 4) | pT2c pN0 pMx |
osc#68 | 69 | 5 | 7 (4 + 3) | pT3a pN0 pMx |
osc#69 | 68 | 5 | 7 (3 + 4) | pT3a pN0 pMx |
osc#70 | 64 | 6,7 | 7 (3 + 4) | pT2c pNx pMx |
osc#71 | 71 | 4,8 | 7 (3 + 4) | pT2c pN0 pMx |
osc#72 | 59 | 5 | 7 (3 + 4) | pT2c pNx pMx |
osc#73 | 57 | 5.4 | 7 (3 + 4) | pT2c pNx pMx |
osc#74 | 69 | 3.9 | 7 (3 + 4) | pT2c pNx pMx |
osc#75 | 79 | 17 | 7 (4 + 3) | pT3a pNx pMx |
osc#76 | 75 | 7 | 7 (4 + 3) | pT2c pN0 pMx |
osc#77 | 49 | 5 | 7 (3 + 4) | pT2c pNx pMx |
osc#78 | 77 | 11.9 | 7 (4 + 3) | pT3a ,pNx,pMx |
osc#79 | 74 | 5.1 | 7 (4 + 3) | pT3b,pNx,pMx |